Enlivex Therapeutics
ENLV
ENLV
20 hedge funds and large institutions have $8.38M invested in Enlivex Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
5% less capital invested
Capital invested by funds: $8.79M → $8.38M (-$406K)
1.64% less ownership
Funds ownership: 6.27% → 4.63% (-1.6%)
Holders
20
Holding in Top 10
–
Calls
$1.65M
Puts
$1.4M
Top Buyers
| 1 | +$183K | |
| 2 | +$171K | |
| 3 | +$102K | |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$101K |
| 5 |
Morgan Stanley
New York
|
+$43.8K |
Top Sellers
| 1 | -$1.06M | |
| 2 | -$563K | |
| 3 | -$191K | |
| 4 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
-$89K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$62.4K |